Orchestra BioMed Holdings Inc Dossier - Source-backed chat

Orchestra BioMed Holdings Inc

OBIONASDAQ

SectorHealth Care

IndustryHealth Care Equipment & Supplies

Beta (adjusted)0.70

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.35Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $381.7M

Enterprise Value $376.2M

Shares Outstanding 60.1M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) is a high-conviction clinical-stage medical technology company utilizing a unique risk-reward sharing partnership model. By collaborating with global giants like Medtronic, Orchestra BioMed significantly reduces its commercialization risk and capital requirements. Its flagship Atrioventricular Interval Modulation (AVIM) Therapy for hypertension is progressing rapidly in the pivotal BACKBEAT trial, with enrollment completion targeted for Q3 2026 and late-breaking data expected in Q2 2027. Backed by a robust cash runway extending into Q4 2027, the company is well-positioned to achieve major clinical and regulatory inflection points.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$12.17

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.00

The BACKBEAT trial experiences enrollment delays or fails to meet its primary efficacy endpoints in Q2 2027, severely damaging the partnership outlook with Medtronic. Cash burn increases faster than expected, forcing highly dilutive equity raises under the ATM facility or other financing arrangements, while the Virtue SAB program faces prolonged clinical or regulatory hurdles.

Base CaseCentral scenario

$13.60

The BACKBEAT trial completes enrollment on schedule in Q3 2026, and clinical data in Q2 2027 is positive, meeting primary safety and efficacy endpoints. Medtronic proceeds with FDA and global regulatory submissions. The company's cash runway remains secure into Q4 2027, supported by structured financing tranches from partners, leading to steady upward valuation adjustment toward consensus targets.

Bull CaseUpside scenario

$20.00

The BACKBEAT trial meets all primary endpoints with superior efficacy, leading to a highly successful late-breaking presentation in Q2 2027. Medtronic rapidly secures FDA approval and aggressively commercializes AVIM Therapy, triggering substantial per-device revenue ($500 to $1,600 per device) and milestone payments. Simultaneously, the Virtue SAB program accelerates, establishing a dominant position in the multi-billion-dollar coronary in-stent restenosis market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

High-impact strategic partnership with Medtronic, which anchors the development and commercialization of AVIM Therapy.
Risk-reward sharing business model that minimizes commercial infrastructure costs and leverages partners' global sales forces.
Strong liquidity position with cash runway projected into Q4 2027, bolstered by recent non-dilutive partner payments ($35 million in May 2026).
Two FDA Breakthrough Device Designations for AVIM Therapy, expanding the addressable U.S. patient population to over 7.7 million adults.

Key Investment Risks

High dependence on clinical trial outcomes, particularly the BACKBEAT trial data expected in Q2 2027.
Reliance on strategic partners (Medtronic) for regulatory submissions, marketing, and commercial execution.
Pre-revenue status with substantial ongoing operating losses ($20.7 million net loss in Q1 2026) and accumulated deficit.
Potential dilution from the utilization of the company's at-the-market (ATM) equity program or convertible preferred stock.

Thesis Invalidation Triggers

Failure of the BACKBEAT trial to meet its primary safety or efficacy endpoints.
Termination or material negative amendment of the strategic collaboration agreement with Medtronic.
Significant delays in BACKBEAT trial enrollment beyond the targeted Q3 2026 completion date.
Severe acceleration of cash burn that depletes liquidity well ahead of the projected Q4 2027 runway.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.